P
Philippe Maingon
Researcher at University of Paris
Publications - 261
Citations - 17363
Philippe Maingon is an academic researcher from University of Paris. The author has contributed to research in topics: Radiation therapy & Prostate cancer. The author has an hindex of 49, co-authored 238 publications receiving 14930 citations. Previous affiliations of Philippe Maingon include European Organisation for Research and Treatment of Cancer & Radboud University Nijmegen.
Papers
More filters
Journal ArticleDOI
Livre blanc de la radiothérapie en France 2013. Douze objectifs pour améliorer un des traitements majeurs du cancer
Journal ArticleDOI
Does the addition of chemotherapy (CT) to preoperative radiotherapy (preopRT) increase the pathological response in patients with resected rectal cancer : Report of the 22921 EORTC phase III trial
J.F. Bosset,Gilles Calais,Laurent Mineur,Philippe Maingon,L. Radosevic-Jelic,Alain Daban,Etienne Bardet,Alexander Beny,Laurence Collette,A. Briffaux +9 more
TL;DR: The addition of 5-FU-LV to preopRT significantly reduced tumor size and pTN stage, and significant decreased LVN invasion rates.
Journal ArticleDOI
Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.
Amar U. Kishan,Fang-I Chu,Christopher R. King,W. Seiferheld,Daniel E. Spratt,Phuoc T. Tran,Xiaoyan Wang,Stephanie E. Pugh,Kiri A. Sandler,Michel Bolla,Philippe Maingon,Theo M. de Reijke,Nicholas G. Nickols,Nicholas G. Nickols,Matthew Rettig,Alexandra Drakaki,Sandy T. Liu,Robert E. Reiter,Albert J. Chang,Felix Y. Feng,Dipti Sajed,Paul L. Nguyen,Patrick A. Kupelian,Michael L. Steinberg,Paul C. Boutros,David Elashoff,Laurence Collette,Howard M. Sandler +27 more
TL;DR: LF is an independent prognosticator of OS, PCSS, and DMFS in high-grade localized PCa and a subset of DM events that are anteceded by LF events that warrant consideration for intervention.
Journal ArticleDOI
Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
Claire Vautravers Dewas,Philippe Maingon,C. Dalban,Aurelie Petitfils,K. Peignaux,Gilles Truc,Etienne Martin,Cedric Khoury,Sylvain Dewas,Gilles Créhange +9 more
TL;DR: This study suggests that further investigations concerning the use of IMRT to treat cancer of the anus are warranted, and a longer follow-up is essential to determine whether or not IMRT has an impact on late toxicity, local control and survival compared with conventional 3D-CRT.
Journal ArticleDOI
Treatment of T1-T2 rectal tumors by contact therapy and interstitial brachytherapy.
TL;DR: The control rate for T1 rectal cancer treated with contact therapy with or without brachytherapy is comparable to surgical series, and Radiotherapy remains an efficient and cheap alternative to surgery, mainly for old and fragile patients, or refusing colostomy.